Lee Ainslie’s Maverick USA is up by about 32% year to date, although it was in the red for the second quarter. Over the last four years, the fund has boosted its exposure to the biotech sector from zero to the highest level in its history. Q2 2021 hedge fund letters, conferences and more Maverick now holds seven different long positions in biotech companies. Ainslie and Company believe they will continue generating meaningful alpha in the sector due to the combination of “durable fundamental tailwinds and structural market inefficiencies.” In the fund’s second-quarter letter to investors, which was reviewed by…
Exclusive: Lee Ainslie’s Maverick Details Thesis For Biotech Sector
Michelle deBoer-Jones
Michelle deBoer-Jones is editor-in-chief of Hedge Fund Alpha. She also writes comparative analyses of stocks for TipRanks and runs Providence Writing Services. Previously, she was a television news producer for eight years, producing the morning news programs for NBC affiliates in Evansville, Indiana and Huntsville, Alabama and spending a short time at the CBS affiliate in Huntsville.